Potential lipid-based strategies of amphotericin B designed for oral administration in clinical application
AbstractAmphotericin B (AmB) is regarded as a first-line therapy against life-threatening invasive fungal infections. Due to its poor oral bioavailability, AmB is restricted to intravenous administration in clinical practice. As science continues to move forward, two lipid-based formulations are suc...
Saved in:
Main Authors: | Xiaoming Zhong (Author), Jianqiong Yang (Author), Hongyan Liu (Author), Zhiwen Yang (Author), Ping Luo (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Design of amphotericin B oral formulation for antifungal therapy
by: Min Liu, et al.
Published: (2017) -
Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats
by: Mahasen A. Radwan, et al.
Published: (2017) -
Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate
by: PH Chandrasekar
Published: (2008) -
Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy
by: Célia Faustino, et al.
Published: (2020) -
Vitamin D deficiency is a potential risk factor for lipid Amphotericin B nephrotoxicity.
by: Daniela Ferreira, et al.
Published: (2019)